Half-year report · HY
4543.TEDINET S100X3VY
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥534.9bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.04T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥101.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥101.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥154.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.89T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥457.3bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥459.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.44T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.37T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.44T | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.37T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥217.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥221.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥102.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥210.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥71.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥38.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥108.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥52.13 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥79.01 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥52.12 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.99 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥163m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.8bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥107.1bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥15.6bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥322.1bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥87.0bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥105.6bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥534.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥116.2bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 630
| Item | Context | Value | Unit |
|---|---|---|---|
| Other current assets ca IFRS | InterimInstant | 23797000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 723496000000 | JPY |
| Current assets IFRS | InterimInstant | 744076000000 | JPY |
| Property plant and equipment IFRS | Prior1YearInstant | 431078000000 | JPY |
| Property plant and equipment IFRS | InterimInstant | 471094000000 | JPY |
| Goodwill and intangible assets IFRS | Prior1YearInstant | 545243000000 | JPY |
| Goodwill and intangible assets IFRS | InterimInstant | 543615000000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 1927000000 | JPY |
| Investments accounted for using equity method IFRS | InterimInstant | 1481000000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 40925000000 | JPY |
| Other financial assets nca IFRS | InterimInstant | 43362000000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 31077000000 | JPY |
| Deferred tax assets IFRS | InterimInstant | 36040000000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 54645000000 | JPY |
| Other non current assets nca IFRS | InterimInstant | 55150000000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 1104897000000 | JPY |
| Non current assets IFRS | InterimInstant | 1150745000000 | JPY |
| Assets IFRS | Prior1YearInstant | 1828393000000 | JPY |
| Assets IFRS | InterimInstant | 1894821000000 | JPY |
| Trade and other payables cl IFRS | Prior1YearInstant | 91029000000 | JPY |
| Trade and other payables cl IFRS | InterimInstant | 101941000000 | JPY |
| Bonds and borrowings cl IFRS | Prior1YearInstant | 15000000000 | JPY |
| Bonds and borrowings cl IFRS | InterimInstant | 59988000000 | JPY |
| Other financial liabilities cl IFRS | Prior1YearInstant | 7834000000 | JPY |
| Other financial liabilities cl IFRS | InterimInstant | 8290000000 | JPY |
| Income taxes payable cl IFRS | Prior1YearInstant | 23836000000 | JPY |
| Income taxes payable cl IFRS | InterimInstant | 27816000000 | JPY |
| Provisions cl IFRS | Prior1YearInstant | 242000000 | JPY |
| Provisions cl IFRS | InterimInstant | 264000000 | JPY |
| Other current liabilities cl IFRS | Prior1YearInstant | 103022000000 | JPY |
| Other current liabilities cl IFRS | InterimInstant | 97996000000 | JPY |
| Total current liabilities IFRS | Prior1YearInstant | 240965000000 | JPY |
| Total current liabilities IFRS | InterimInstant | 296298000000 | JPY |
| Bonds and borrowings ncl IFRS | Prior1YearInstant | 159838000000 | JPY |
| Bonds and borrowings ncl IFRS | InterimInstant | 99885000000 | JPY |
| Other financial liabilities ncl IFRS | Prior1YearInstant | 32401000000 | JPY |
| Other financial liabilities ncl IFRS | InterimInstant | 35056000000 | JPY |
| Deferred tax liabilities IFRS | Prior1YearInstant | 5835000000 | JPY |
| Deferred tax liabilities IFRS | InterimInstant | 5650000000 | JPY |
| Retirement benefit liability ncl IFRS | Prior1YearInstant | 6388000000 | JPY |
| Retirement benefit liability ncl IFRS | InterimInstant | 6552000000 | JPY |
| Provisions ncl IFRS | Prior1YearInstant | 617000000 | JPY |
| Provisions ncl IFRS | InterimInstant | 903000000 | JPY |
| Other non current liabilities ncl IFRS | Prior1YearInstant | 13809000000 | JPY |
| Other non current liabilities ncl IFRS | InterimInstant | 12937000000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 218891000000 | JPY |
| Non current labilities IFRS | InterimInstant | 160985000000 | JPY |
| Liabilities IFRS | Prior1YearInstant | 459857000000 | JPY |
| Liabilities IFRS | InterimInstant | 457284000000 | JPY |
| Share capital IFRS | Prior1YearInstant | 38716000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |